1-ethylcyclobutanecarbaldehyde | 443796-58-5

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氧化物
• 英文名称: 1-ethylcyclobutanecarbaldehyde
• 英文别名: 2,2-Trimethylenebutan-1-al；2,2-(trimethylene)butanal；1-ethylcyclobutane-1-carbaldehyde
• CAS: 443796-58-5
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: FTHUFBUZFDIYSA-UHFFFAOYSA-N

物化性质

• 沸点：
  138.8±9.0 °C(Predicted)
• 密度：
  0.987±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-ethylcyclobutanecarbaldehyde 在 2,6-二甲基吡啶 、 三甲基氯硅烷 、 偶氮二异丁腈 、 叔丁基锂 、 三正丁基氢锡 、 magnesium 、 lithium,azanidylidenemethylidenecopper,2H-thiophen-2-ide 、 mercury dichloride 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 正戊烷 为溶剂， 反应 8.51h， 生成 4-(2-{(1R,2R,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-4-(tert-butyl-dimethyl-silanyloxy)-4-(1-ethyl-cyclobutyl)-but-1-enyl]-5-oxo-cyclopentyl}-ethyl)-benzoic acid methyl ester
  参考文献：
  名称：

  Development of a highly selective EP2-receptor agonist. Part 1: identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives

  摘要：

  Design and synthesis of an EP2-receptor selective agonist began with the chemical modification of alpha- and omega-chains of butaprost 1a, which exhibits an affinity for the IP-receptor. Two series of prostaglandin (PG) analogues with a 16-hydroxy-17,17-trimethylene moiety as an omega-chain were identified. Among those tested, 4a,b,e,f,h and 6a,b,e,f,h were found to be highly selective EP2-receptor agonists. Structure activity relationships are discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00369-8
• 作为产物：
  描述：

  环丁基甲酸 在 lithium aluminium tetrahydride 、 草酰氯 、 二甲基亚砜 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 17.0h， 生成 1-ethylcyclobutanecarbaldehyde
  参考文献：
  名称：

  Development of a highly selective EP2-receptor agonist. Part 1: identification of 16-hydroxy-17,17-trimethylene PGE2 derivatives

  摘要：

  Design and synthesis of an EP2-receptor selective agonist began with the chemical modification of alpha- and omega-chains of butaprost 1a, which exhibits an affinity for the IP-receptor. Two series of prostaglandin (PG) analogues with a 16-hydroxy-17,17-trimethylene moiety as an omega-chain were identified. Among those tested, 4a,b,e,f,h and 6a,b,e,f,h were found to be highly selective EP2-receptor agonists. Structure activity relationships are discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00369-8

文献信息

• OIL GELATOR
  申请人：NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY

  公开号：US20180362454A1

  公开（公告）日：2018-12-20

  There is provided a novel gelator containing a monourea derivative. A gelator comprising a compound of formula (1): wherein R 1 is a linear or branched alkyl group having a carbon atom number of 2 to 20, a cyclic alkyl group having a carbon atom number of 3 to 20, or a linear or branched alkenyl group having a carbon atom number of 12 to 20; and Ar is a C 6-18 aryl group unsubstituted or optionally substituted with at least one substituent selected from the group consisting of a C 1-10 alkyl group, a C 1-10 alkoxy group, a C 6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C 2-10 alkylcarbonyl group, and a C 7-18 aralkyl group.

  提供了一种含有单脲衍生物的新型凝胶剂。一种包含化合物的凝胶剂，其化学式为(1)：其中R1为具有2至20个碳原子数的线性或支链烷基基团，具有3至20个碳原子数的环烷基基团，或具有12至20个碳原子数的线性或支链烯基基团；Ar为未取代或可选择地取代至少一种取代基的C6-18芳基基团，所述取代基选自C1-10烷基基团、C1-10烷氧基基团、C6-18芳氧基基团、卤原子、硝基基团、苯基、C2-10烷基羰基基团和C7-18芳基烷基基团。
• NOVEL HYDROGELATOR
  申请人：NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY

  公开号：US20190241598A1

  公开（公告）日：2019-08-08

  A novel hydrogelator that contains a monourea compound having a sugar structure, which can be produced by a simple method, includes a compound of the following Formula [1]: (wherein S g is a sugar group, A is a divalent linking group, and R is a linear or branched alkyl group having a carbon atom number of 1 to 15, a cyclic alkyl group having a carbon atom number of 3 to 15, a linear or branched alkenyl group having a carbon atom number of 2 to 15, or a C 6-18 aryl group unsubstituted or substituted with at least one substituent selected from the group consisting of a C 1-10 alkyl group, a C 1-10 alkoxy group, a C 6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C 2-10 alkylcarbonyl group, and a C 7-18 aralkyl group).

  一种新型水凝胶剂，包含具有糖结构的单脲化合物，可以通过简单的方法制备，包括以下式[1]的化合物：（其中S是糖基，A是二价连接基团，R是线性或支链烷基，碳原子数为1至15，环状烷基，碳原子数为3至15，线性或支链烯基，碳原子数为2至15，或未取代或取代至少一个取代基的C6-18芳基，所述取代基选择自C1-10烷基，C1-10烷氧基，C6-18芳氧基，卤素原子，硝基，苯基，C2-10烷基羰基和C7-18芳基烷基组成）。
• 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
  申请人：Buchmann Bernd

  公开号：US20070203096A1

  公开（公告）日：2007-08-30

  The present invention relates to 9-chloroprostaglandin derivatives of the general formula I which may be advantageous for the treatment of fertility problems.

  本发明涉及一般式I的9-氯前列腺素衍生物，可能对治疗生育问题有益。
• [EN] PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS<br/>[FR] COMPOSES DE PYRAZOLIDINONE UTILISES COMME LIGANDS DES RECEPTEURS EP2 ET/OU EP4 AUX PROSTAGLANDINES
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003035064A1

  公开（公告）日：2003-05-01

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  本发明提供了取代吡唑烷酮化合物，以及利用或包含一个或多个这样的化合物的治疗方法和制药组合物。本发明的化合物可用于多种治疗，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血液凝块、先兆子痫或子痫、嗜酸性粒细胞障碍、性功能障碍、骨质疏松症和其他破坏性骨疾病或障碍，以及与前列腺素EP2和/或EP4受体相关的其他疾病和障碍。
• Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
  申请人：——

  公开号：US20040254233A1

  公开（公告）日：2004-12-16

  The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

  本发明提供了取代吡唑啉酮化合物，以及利用或包含一个或多个这样的化合物的治疗方法和制药组合物。本发明的化合物对于各种疗法都有用，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血栓形成、先兆子痫或子痫、嗜酸性粒细胞异常、性功能障碍、骨质疏松症和其他破坏性骨疾病或疾病，以及与前列腺素EP2和/或EP4受体相关的其他疾病和疾病。